Researchers have developed a novel vaccine and complementary skin test to protect cattle against bovine tuberculosis (bovine TB). The study, published in the journal Scientific Reports, revealed that the research team from the University of Surrey created a vaccine that is compatible with a synthetic form of the tuberculin skin test(PPD), a legally required test used for the surveillance of TB in cattle throughout the UK.

Measles MMR
A vial of the measles, mumps, and rubella virus (MMR) vaccine.Reuters

"This new vaccine provides protection against bovine TB and will help in the fight against this deadly disease which infects over 50 million cattle worldwide and is economically devastating to farmers," said study researcher Johnjoe McFadden Bovine TB is an infectious disease in cattle affecting their lungs, and those that test positive for the disease are culled.

The Bacille Calmette Guerin (BCG) vaccine, which is currently used to protect humans against TB and is effective in cattle, is incompatible with the PPD test. During this study, researchers sought to make a new BCG vaccine strain that lacks some of the proteins that are shared with the pathogen Mycobacterium bovis by identifying genes that contain encoded immunogenic proteins that could be removed from BCG without affecting its ability to work as a live vaccine.

To do this, a collection of BCG strains that had each lost a single gene were injected into cows and survival rates measured. This allowed the team to identify genes that could be removed without compromising the BCG vaccine's effectiveness. These dispensable genes encoding immunogenic proteins were then deleted from the BCG chromosome to make a BCG-minus strain.

Immunogenic proteins used to develop a new synthetic skin test

Vaccine
[Representational image]Creative Commons

The deleted immunogenic proteins were then used to develop a new synthetic skin test that, like PPD, will be positive for animals that have been exposed to TB but, unlike PPD, will be negative for animals that have been vaccinated with the BCG-minus strain. The protective efficiency of the new strain was tested in guinea pigs.

It was found that TB-infected guinea pigs tested positive for the disease using the synthetic skin test whilst guinea pigs vaccinated with the BCG-minus strain did not. So, unlike PPD, the new skin test also works in animals that are protected from TB by BCG-minus vaccination. This potentially allows farmers and veterinarians to protect their animals with the new BCG vaccine, whilst still maintaining a diagnostic test that will detect TB.